(Información remitida por la empresa firmante)
Bioretec is?developing?the new RemeOs™?product line?based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on?value for patients through efficient healthcare. The first RemeOs™ product market authorizations are expected in the U.S. during April 2023 and in Europe during 2023. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical possibilities. Better healing – Better life. www.bioretec.com
Appendix
Bioretec Ltd’s financial statements bulletin January-December 2022 (pdf)
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/bioretec-ltds-financial-statements-bulletin-2022-we-are-delighted-about-the-sales-growth-and-look-forward-to-future-approvals-301749566.html